By Denny Jacob
Pharmaceutical company Moderna Inc. on Thursday said its mRNA-4157/V940 in combination with drugmaker Merck & Co.’s Keytruda was granted priority medicines scheme designation by the European Medicines Agency to treat patients with high-risk stage III/IV melanoma following complete resection.
The companies said the designation…
Read the full article here